Poseida Therapeutics, Inc. Stock Price, News & Analysis

Poseida Therapeutics (NASDAQ: PSTX) announced the appointment of Brent Warner as President, Gene Therapy, effective February 21, 2022. Warner brings over 15 years of experience in the biotech sector, previously holding senior roles at Novartis and BioMarin. His expertise will drive the company’s gene therapy programs, particularly a recent collaboration with Takeda. CEO Mark Gergen expressed optimism about Warner's leadership, aligning with Poseida's mission to advance innovative gene therapies for rare diseases.

Poseida Therapeutics (Nasdaq: PSTX) announced interim results from its Phase 1 trial of P-PSMA-101, an autologous CAR-T product for metastatic castrate-resistant prostate cancer (mCRPC), presented at the ASCO GU Symposium. Out of 14 evaluable patients, 71% showed PSA declines, with one achieving complete tumor elimination. The trial demonstrated a favorable safety profile, with manageable adverse events, including cytokine release syndrome. The ongoing study aims to further assess safety and efficacy, utilizing Poseida's proprietary genetic engineering technologies.

Poseida Therapeutics (Nasdaq: PSTX) will hold its second annual Virtual R&D Day on February 23, 2022, from 10:00 am to 1:30 pm ET. The event will feature presentations from executives, researchers, and key opinion leaders, focusing on the company's genetic engineering technologies and cell and gene therapy programs. Notable speakers include Dr. Susan F. Slovin from Memorial Sloan Kettering and Dr. Luca Gattinoni from the University of Regensburg. Registration is available on Poseida's website, with a replay of the webcast accessible for 30 days after the event.

Poseida Therapeutics, Inc. (Nasdaq: PSTX) announced the appointment of Eric Ostertag as Executive Chairman and Mark Gergen as CEO effective February 1, 2022. Both will continue on the Board of Directors. The company is focusing on advancing its gene and cell therapy programs, including partnerships with Takeda, valued at up to $3.6 billion. Poseida also outlined its 2022 objectives, highlighting ongoing clinical trials for its P-PSMA-101 and P-BCMA-ALLO1 product candidates. The company’s R&D Day is set for February 23, 2022, to showcase progress and future strategies.

Poseida Therapeutics (Nasdaq: PSTX) announced FDA clearance for its Investigational New Drug (IND) application for P-MUC1C-ALLO1, an allogeneic CAR-T product targeting solid tumors. This marks Poseida's second IND clearance in 2021, following P-BCMA-ALLO1. The upcoming Phase 1 trial will evaluate P-MUC1C-ALLO1's safety and efficacy in patients with advanced epithelial-derived solid tumors. The product is designed to reduce alloreactivity, potentially allowing treatment from a single manufacturing run. Initial clinical data is expected in 2022.

Poseida Therapeutics (PSTX) announced interim results from its Phase 1/2 PRIME clinical trial for P-BCMA-101, a CAR-T therapy for relapsed/refractory multiple myeloma, at the 2021 ASH Annual Meeting. The therapy was well tolerated, showing a 78% overall response rate and significant anti-tumor activity. The company is transitioning to its allogeneic program, P-BCMA-ALLO1, which leverages insights from the trial. The IND for P-BCMA-ALLO1 was approved by the FDA in August 2021, with expectations to present more data in 2022.

Poseida Therapeutics (Nasdaq: PSTX) reported its third-quarter 2021 program updates and financial results, demonstrating progress in clinical trials and partnerships. FDA cleared the IND for P-BCMA-ALLO1, their first allogeneic CAR-T therapy, focusing on multiple myeloma. The company revealed a collaboration with Takeda, earning $45 million to develop gene therapies. Research and development expenses rose to $32.5 million, leading to a net loss of $42.4 million for the quarter. As of September 30, 2021, Poseida held $197.8 million in cash and equivalents.

Poseida Therapeutics (PSTX) announced the presentation of preclinical data for its allogeneic CAR-T candidates, P-BCMA-ALLO1 and P-MUC1C-ALLO1, at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting from November 10-14. The data highlights potent antitumor activity and the benefits of their proprietary genetic engineering technologies. P-BCMA-ALLO1 has received FDA IND clearance and is entering Phase 1 trials. The company aims to leverage its manufacturing process to produce numerous patient doses, potentially reducing costs significantly.

Poseida Therapeutics (Nasdaq: PSTX) announced participation in two upcoming virtual investor conferences. The Stifel 2021 Virtual Healthcare Conference is scheduled for November 16, 2021, at 2:40 PM ET, while the Piper Sandler 33rd Annual Virtual Healthcare Conference will take place on November 22, 2021, with a pre-record available at 10:00 AM ET. Webcasts will be accessible on the Poseida website for 30 days post-event. Poseida utilizes proprietary genetic engineering to develop advanced cell and gene therapeutics.